GSK Looks To Long-Acting Therapy To Restore Lead In HIV

Targeting HIV Cure By 2030

 
• By Andrew McConaghie

GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.

GSK syringes
Cabenuva has got off to a slow start thanks to the pandemic, but GSK hope it can become a multi-billion dollar product • Source: Alamy

More from Business

More from Scrip